Reference - Detail
RRC ID | 54045 |
---|---|
Author | Shimizu K, Okita R, Saisho S, Maeda AI, Nojima Y, Nakata M. |
Title | Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer. |
Journal | Anticancer Res |
Abstract |
BACKGROUND/AIM:There is no clear evidence in the literature regarding the regulation of programmed cell death-ligand 1 (PD-L1) expression by cyclo-oxygenase-2 (COX2). In this study, whether PD-L1 expression was regulated by COX2 activity was examined in vitro. MATERIALS AND METHODS:Resected lung cancer specimens were analyzed for PD-L1 and COX2 expression by immunohistochemical analysis. Next, co-localization of PD-L1 and COX2 expression was analyzed by double-fluorescence staining. Lastly, the effect of COX2 inhibition on the expression of PD-L1 was examined using lung cancer cell lines. RESULTS:PD-L1 expression was significantly correlated with COX2 expression in the resected specimens. The majority of cancer cells that expressed PD-L1 also co-expressed COX2. However, treatment of lung cancer cell lines with a COX2 inhibitor had no impact on PD-L1 expression. CONCLUSION:Our results suggest that COX2 inhibition might have no effect on the usage of immune checkpoint inhibitors in lung cancer treatment. |
Volume | 38(8) |
Pages | 4637-4644 |
Published | 2018-8-1 |
DOI | 10.21873/anticanres.12768 |
PII | 38/8/4637 |
PMID | 30061230 |
MeSH | A549 Cells B7-H1 Antigen / metabolism* Carcinoma, Non-Small-Cell Lung / drug therapy* Carcinoma, Non-Small-Cell Lung / metabolism Cell Line, Tumor Cyclooxygenase 2 / metabolism* Cyclooxygenase 2 Inhibitors / pharmacology* Gene Expression Regulation, Neoplastic / drug effects Humans Lung Neoplasms / drug therapy* Lung Neoplasms / metabolism |
IF | 1.994 |
Times Cited | 7 |
Resource | |
Human and Animal Cells | RERF-LC-AI(RCB0444) A549 LC-2/ad(RCB0440) |